A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F

Journal:
Journal of Biological Chemistry
Published:
DOI:
10.1016/j.jbc.2025.111056
Affiliations:
6
Authors:
15
Go to article
Institutions Authors Share
The Hong Kong University of Science and Technology (HKUST), China
6.666667
 0.44
aTyr Pharma, Inc., United States of America (USA)
4.000000
 0.27
IAS HKUST - Scripps R&D Laboratory, China
1.666667
 0.11
Pangu Biopharma Ltd., China
1.666667
 0.11
Scripps Research, United States of America (USA)
1.000000
 0.07
Interested in Oncology and Carcinogenesis?